Vor Biopharma Inc. (VOR) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Company: Vor Biopharma Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Vor Biopharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases. In June 2025, the company executed a strategic pivot, winding down its previous blood cancer programs (trem-cel, VCAR33) and in-licensing telitacicept from RemeGen Co., Ltd. Vor holds exclusive rights to develop and commercialize telitacicept outside of Greater China. Telitacicept is a dual-target fusion protein (BAFF/APRIL) approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). Vor is currently conducting global Phase 3 trials for gMG and Sjögren's disease (SjD).
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(696.0) | $(116.9) |
| Net Loss Per Share (Basic & Diluted) | $(70.50) | $(34.03) |
| Research & Development Expenses | $321.5 | $93.3 |
| General & Administrative Expenses | $50.1 | $27.9 |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $455.2 | $91.9 |
| Accumulated Deficit (Dec 31, 2025) | $(1,153.0) | $(457.0) |
| Warrant Liabilities (Dec 31, 2025) | $600.5 | $0.0 |
Note: The company has no revenue and operates at a loss. Margins are not applicable.
Material Changes vs. Prior Period
- Strategic Pivot & Restructuring: In May 2025, the company announced a restructuring plan, reducing its workforce by approximately 99% (154 employees) and winding down prior clinical programs. This resulted in $29.7 million in restructuring costs during 2025.
- Telitacicept Acquisition: The company incurred a non-cash charge of $222.6 million in R&D expenses related to the acquisition of the telitacicept license from RemeGen. This included a $45 million cash payment and the issuance of a warrant valued at $177.4 million.
- Warrant Liability Volatility: A significant non-cash loss of $334.4 million was recorded due to the change in fair value of liability-classified warrants issued in connection with the license agreement and private placements.
- Capital Raises: The company raised substantial capital in 2025 through multiple transactions, including a June 2025 private placement ($174.4M net), a November 2025 public offering ($107.7M net), and a December 2025 private placement ($149.9M net).
- Reverse Stock Split: A 1-for-20 reverse stock split was effected in September 2025.
Guidance, Outlook, and Risks
Outlook & Liquidity: As of December 31, 2025, the company held $455.2 million in cash and marketable securities. Management expects these funds, combined with proceeds from a March 2026 private placement (expected gross proceeds of $75.0 million), to fund operations into early 2029. The company anticipates continuing to incur significant operating losses as it advances global Phase 3 trials.
Clinical Milestones:
- gMG: Global Phase 3 trial is recruiting; topline data expected in the first half of 2027.
- SjD: Global Phase 3 trial initiated with first patient dosing in March 2026.
Key Risks:
- Dependence on Telitacicept: The company's future is entirely dependent on the success of this single product candidate.
- Regulatory Uncertainty: No assurance that data from RemeGen's trials in China will be accepted by the FDA or EMA.
- Capital Requirements: Substantial additional funding will be required; failure to raise capital could force delays or elimination of programs.
- Intellectual Property: High dependence on third-party licensed IP from RemeGen; termination of the license would be catastrophic.
- Warrant Liability: Significant volatility in net loss due to mark-to-market adjustments on warrant liabilities.
Investor Verification Checklist
- License Agreement Terms: Verify the specific milestone payments ($330M regulatory, $3.775B sales) and royalty rates owed to RemeGen.
- Warrant Liability Valuation: Review the assumptions used to value the $600.5 million warrant liability and its impact on future earnings volatility.
- Cash Runway: Confirm the closing of the March 2026 private placement and monitor burn rate against the "early 2029" liquidity projection.
- Clinical Trial Enrollment: Monitor patient enrollment rates in the global Phase 3 trials for gMG and SjD, as delays could significantly impact the 2027 data readout.
- Regulatory Strategy: Assess the FDA's acceptance of RemeGen's Chinese clinical data for the BLA submission.